Quarterly ResultAug 5, 2026, 04:53 PM
BioAge Doses First Patient in QUELL-CV Phase 2; Q2 Net Loss $26.1M
AI Summary
BioAge Labs announced that the first participant was dosed in QUELL-CV, a Phase 2 trial for its lead candidate BGE-102, with topline data expected in H2 2026. The company also plans to initiate the QUELL-DME Phase 1b/2a trial for BGE-102 in diabetic macular edema in mid-2026. For Q2 2026, BioAge reported a net loss of $26.1 million and R&D expenses of $24.4 million. The company maintains a strong cash position of $381.3 million, providing a runway through 2029.
Key Highlights
- First participant dosed in QUELL-CV Phase 2 trial for BGE-102.
- QUELL-DME Phase 1b/2a trial for BGE-102 to initiate mid-2026.
- Q2 2026 Net Loss was $26.1 million, or $0.58 per share.
- Q2 2026 R&D expenses increased to $24.4 million from $19.8 million YoY.
- Collaboration revenue for Q2 2026 was $2.4 million.
- Cash, cash equivalents, and marketable securities totaled $381.3 million.
- Company estimates existing cash runway through 2029.
- IND for APJ agonist program planned by year-end 2026.
Price Impact
More from BIOA